(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 10 February 2005 (10.02.2005)

PCT

(10) International Publication Number WO 2005/011652 A3

(51) International Patent Classification⁷: A61K 31/592, 31/593, 45/06, A61P 13/12, A61K 9/00, 9/70

(21) International Application Number:

PCT/US2004/024517

(22) International Filing Date: 29 July 2004 (29.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/491,025 29 July 2003 (29.07.2003)

(71) Applicant (for all designated States except US): ABBOTT LABORATORIES [US/US]; Dept. 377 Bldg AP6A-1, 100 Abbott Park Road, Abbott Park, IL 60064-6008 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MELNICK, Joel


[US/US]; 408 Brookside Dr., Wilmette, IL 60091 (US). TIAN, Jin [US/US]; 1360 S. White Oak Dr., Waukegan, IL 60085 (US). WILLIAMS, Laura [US/US]; 1150 Hadley Circle, Gurnee, Gurnee, IL 60031 (US). DELGADO-HERRERA, Leticia [US/US]; 2020 South Meadow Lane, Lake Forest, IL 60045 (US).

(74) Agents: COLEMAN-JAMES, Patricia et al.; Dept. 377 Bldg AP6A-1, 100 Abbott Park Road, Abbott Park, IL 60064-6008 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: USE OF A VITAMIN D RECEPTOR ACTIVATOR OR A VITAMIN D ANALOG TO TREAT KIDNEY DISEASE



Paricalcitol inhibits renin mRNA expression in AS4.1 cells. A. As4.1-hVDR cells were treated with ethanol (E), calcitriol or paricalcitol at indicated concentrations for 24 hours and renin mRNA expression was determined by Northern blot. B. Quantitative renin mRNA data, obtained from three independent Northern blot analyses. *, P<0.001 vs. ethanol-treated control.

(57) Abstract: The present invention relates to the use of Vitamin D receptor activator or Vitamin D analog, preferably paricalcitol, to treat, prevent and delay progression of kidney dissease. According to one embodiment, the compounds are provided in a sustained release pharmaceutical composition. According to another embodiment, the Vitamin D receptor activator or Vitamin D analog is combined with at least one of an angiotensin converting enzyme inhibitor, an angiotensin (II) receptor (I) blocker or an aldosterone blocker.

WO 2005/011652 A3



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 23 June 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

International Application No PCT/US2004/024517

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/592 A61K31/593 A61K45/06 A61P13/12 A61K9/00 A61K9/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7-A61K

O POOLIMENTS CONCIDEDED TO BE BELEVANT

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, SCISEARCH, CHEM ABS Data

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the r	elevant passages	Relevant to claim No.
X	US 5 597 815 A (SLATOPOLSKY EDU AL) 28 January 1997 (1997-01-28 column 1, line 64 - column 2, l column 2, line 26 - line 51 column 4, line 19 - line 22 column 4, line 45 - line 49 claims 1,4,8-10)	1,3,4, 10-12, 18-20
X	US 4 230 701 A (HOLICK MICHAEL 28 October 1980 (1980-10-28) column 3, line 5 - line 34 column 4, line 47 - column 5, l column 5, line 48 - line 55 column 6, line 56 - line 60	·	1,2,10, 11,18,19
X Furti	ner documents are listed in the continuation of box C.	X Patent family members are listed i	n annex.
"A" docume consid "E" earlier of filing d "L" docume which citation "O" docume other i "P" docume	int which may throw doubts on priority claim(s) or is cited to establish the publication date of another nor other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	"T" later document published after the inte or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the do "Y" document of particular relevance; the cannot be considered to involve an involve and its combined with one or moments, such combination being obvious in the art. "&" document member of the same patent	the application but ecory underlying the laimed invention be considered to cument is taken alone laimed invention ventive step when the ore other such docuus to a person skilled
Date of the	actual completion of the international search	Date of mailing of the international sea	rch report
7	December 2004	0 6. 05. 2005	
Name and r	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Cielen, E	
orm PCT/ISA/	210 (second sheet) (January 2004)		

C (Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PC1/052004/02451/
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 614 513 A (KNUTSON JOYCE C ET AL) 25 March 1997 (1997-03-25)	1,2,5, 10,11, 13,18, 19,21
	column 1, line 10 - line 14 column 2, line 48 - column 3, line 7 column 4, line 26 - line 34 column 8, line 23 - line 46 example 9	
Х	US 6 329 357 B1 (OKAMURA WILLIAM H ET AL) 11 December 2001 (2001-12-11)	1,6,7,9, 10,14, 15,17, 18,22,23
	column 1, line 25 - line 49 column 29, line 12 - line 20 column 36, line 1 - line 18 claims 1,2	,
X	US 2002/128241 A1 (HAYES COLLEEN E ET AL) 12 September 2002 (2002-09-12) page 1, paragraph 1 page 2, paragraphs 14,24 page 3, paragraphs 26,29 page 4, paragraphs 36,39 page 7, paragraph 67	1-5, 10-13
X	WO 98/51663 A (HOFFMANN LA ROCHE ; WOMEN & INFANT S HOSPITAL (US)) 19 November 1998 (1998-11-19)	1,4-8, 10, 12-16, 18-23
	page 3, line 4 - line 23 page 13, line 16 - line 30 page 17, line 6 - line 12 page 18, line 11 - line 15 page 19, line 1 - line 6 page 19, line 29 - page 20, line 9 page 32, line 22 - line 29 claims 1,14,15,23,24	
X	EP 1 179 346 A (DOI TOSHIO) 13 February 2002 (2002-02-13) column 1, paragraph 1 column 3, paragraph 27 column 4, paragraphs 31,32 column 6, paragraph 43 claims 1-3	1,4,10, 12,18-20
	-/	

C (Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PC1/052004/02451/
Category °		Relevant to claim No.
X	US 2002/045606 A1 (REDDY SATYANARAYANA GET AL) 18 April 2002 (2002-04-18) page 1, paragraph 6 - page 2, paragraph 14 page 3, paragraphs 18,29,30 page 4, paragraph 39 page 11, paragraphs 100,106 page 12, paragraphs 111,116,117 page 16, paragraph 150 claims 1,49,50	1,4-8, 10, 12-16, 18-23
X	WO 03/050067 A (BERNARDON JEAN-MICHEL; BIADATTI THIBAUD (FR); GALDERMA RES & DEV (FR)) 19 June 2003 (2003-06-19) page 1, line 3 - line 4 page 2, line 10 - line 25 page 7, line 16 - page 9, line 34	1,4,5, 10,12, 13,18-21
X	PACKARD M J: "VARIATION DURING DEVELOPMENT IN THE RESPONSE OF CHICKEN EMBRYOS TO CALCITRIOL ADMINISTERED VIA SLOW-RELEASE PELLETS" GENERAL AND COMPARATIVE ENDOCRINOLOGY, vol. 85, no. 1, 1992, pages 17-25, XP008039634 ISSN: 0016-6480 abstract page 18, column 1, paragraph 3	1,2,6, 9-11,17
P,X	WO 2004/028515 A (CHOI YOUNG-KWEON) 8 April 2004 (2004-04-08) page 6, line 15 - page 7, line 17 examples 1,8 page 20, lines 19-21 claims 1,2,10	1-4, 10-12, 18-20
P,X	WO 2004/016273 A (MATHES ANGELO; MARX STEVEN E (US); ABBOTT LAB (US); MELNICK JOEL Z (U) 26 February 2004 (2004-02-26) page 2, line 36 - page 3, line 3 page 6, line 2 - line 16 claims 1-7,11,13,14,16,17	1-23
E	WO 2004/080467 A (BONE CARE INT INC; STRUGNELL STEPHEN A (US); KNUTSON JOYCE C (US); MA) 23 September 2004 (2004-09-23) page 1, line 9 - line 11 page 5, line 13 - line 20 page 7, line 6 - page 8, line 19 page 9, line 24 - line 27 page 11, line 21 - page 16, line 9 page 18, line 18 - line 29 claims 1,2,4,7	1,2, 5-11, 13-19, 21-23

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 18-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-23 (all partially)
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-23 (all partially)

A sustained release pharmaceutical composition or a pharmaceutical composition for preventing, treating and delaying the progression of kidney disease comprising a therapeutically effective amount of vitamin D receptor activator or vitamin D analog without an ACE inhibitor, an AT(II) receptor (I) blocker or an aldosterone blocker. A method for preventing, treating and delaying the progression of kidney disease in a mammal comprising the step of administering to said mammal such a composition.

2. claims: 1-23 (all partially)

A sustained release pharmaceutical composition or a pharmaceutical composition for preventing, treating and delaying the progression of kidney disease comprising a therapeutically effective amount of vitamin D receptor activator or vitamin D analog and a therapeutically effective amount of at least one member of the group consisting of an ACE inhibitor, an AT(II) receptor (I) blocker or an aldosterone blocker. A method for preventing, treating and delaying the progression of kidney disease in a mammal comprising the step of administering to said mammal such a composition.

				FC1/0.	52004/02451/
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5597815	A	28-01-1997	AT AU CA DE EP JP JP NZ WO	290868 T 705895 B2 6636496 A 2224284 A1 69634483 D1 0837681 A2 3255926 B2 11502862 T 313816 A 9702826 A2	15-04-2005 03-06-1999 10-02-1997 30-01-1997 21-04-2005 29-04-1998 12-02-2002 09-03-1999 29-06-2001 30-01-1997
US 4230701	Α	28-10-1980	US	4335120 A	15-06-1982
US 5614513	A	25-03-1997	US AT AU CA DE DK EP S VS US US US	5529991 A 5795882 A 211387 T 4645893 A 696402 B2 6060896 A 2116238 A1 69331409 D1 69331409 T2 600079 T3 0600079 A1 2170069 T3 7501343 T 254424 A 9400128 A1 5622941 A 6150346 A 6147064 A 6133250 A	25-06-1996 18-08-1998 15-01-2002 24-01-1994 10-09-1998 03-10-1996 06-01-1994 07-02-2002 29-08-2002 15-04-2002 08-06-1994 01-08-2002 09-02-1995 22-09-1997 06-01-1994 22-04-1997 21-11-2006 14-11-2006
US 6329357	B1	11-12-2001	US AU CA EP WO US US AU CA EP JP WO	6103709 A 9503598 A 2304056 A1 1021193 A1 2001517706 T 9916452 A1 6121469 A 2001014749 A1 1445295 A 2179288 A1 0737070 A1 9507079 T 9517197 A1	15-08-2000 23-04-1999 08-04-1999 26-07-2000 09-10-2001 08-04-1999 19-09-2000 16-08-2001 10-07-1995 29-06-1995 15-07-1997 29-06-1995
US 2002128241	A1	12-09-2002	US AU CA EP JP NO WO US	6358939 B1 2287801 A 2395200 A1 1240136 A1 2004502638 T 20022974 A 0146132 A1 2003109506 A1	19-03-2002 03-07-2001 28-06-2001 18-09-2002 29-01-2004 20-08-2002 28-06-2003
WO 9851663	Α	19-11-1998	AU US	7497798 A 2001007907 A1	08-12-1998 12-07-200

						·
Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9851663	Α		WO US	9851663 2003171605		19-11-1998 11-09-2003
EP 1179346	Α	13-02-2002	AU EP US WO US	4146000 1179346 6506741 0067758 2003083320	A1 B1 A1	21-11-2000 13-02-2002 14-01-2003 16-11-2000 01-05-2003
US 2002045606	A1	18-04-2002	AU WO	2058701 0140177		12-06-2001 07-06-2001
WO 03050067	А	19-06-2003	FR AU BR CA EP WO US	2833258 2002366578 0215124 2468892 1456160 03050067 2003195259	A1 A1 A2 A2	13-06-2003 23-06-2003 03-11-2004 19-06-2003 15-09-2004 19-06-2003 16-10-2003
WO 2004028515	Α	08-04-2004	WO AU	2004028515 2002368245		08-04-2004 19-04-2004
WO 2004016273	A	26-02-2004	AU WO	2003258282 2004016273		03-03-2004 26-02-2004
WO 2004080467	Α	23-09-2004	US WO	2004043971 2004080467		04-03-2004 23-09-2004